AZNAstraZenecaRunning, no new patients
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Biliary Tract Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 760 (final count)
- Started
- Dec 4, 2023
- Main results expected
- Jan 2, 2029
- Fully finished
- May 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence free survival (RFS) for Arm A vs. Arm B
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06109779 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC